Dr Gretchen Anne Hayden, DOCTOR OF PHARMACY | |
165 Walnut, Arlington, KY 42021 | |
(270) 655-6151 | |
(270) 655-6301 |
Full Name | Dr Gretchen Anne Hayden |
---|---|
Gender | Female |
Speciality | Pharmacist |
Location | 165 Walnut, Arlington, Kentucky |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1215100821 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
183500000X | Pharmacist | 013293 (Kentucky) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Gretchen Anne Hayden, DOCTOR OF PHARMACY 189 Pleasure Dr, Mayfield, KY 42066-6956 Ph: (270) 655-6151 | Dr Gretchen Anne Hayden, DOCTOR OF PHARMACY 165 Walnut, Arlington, KY 42021 Ph: (270) 655-6151 |
News Archive
Children who have chronic sleep problems may be much more likely to develop mental health disorders as adolescents and adults, according to Candice Alfano, associate professor in clinical psychology at the University of Houston (UH) and director of the new Sleep and Anxiety Center for Kids (SACK).
Nearly 80 percent of chronic hepatitis C sufferers who have the disease for several decades will develop cirrhosis or end-stage liver disease later in life, according to a study published today in the American Gastroenterological Association (AGA) journal Clinical Gastroenterology and Hepatology.
High levels of 'bad' cholesterol (LDL cholesterol) are a risk factor for developing atherosclerotic cardiovascular disease (ASCVD) - a disease of the major arterial blood vessels that is one of the major causes of heart attack and stroke.
After a recent death of a four year old girl following an inquest at the regional Doomadgee hospital in northwest of Queensland on 23rd July 2009, a severe doctor shortage in the region has been finally realised, despite the availibility of skilled pediatricians.
Medarex, Inc. has announced the allowance of an investigational new drug (IND) application filed with the U.S. Food & Drug Administration (FDA) for MDX-1203, the Company's first Antibody-Drug Conjugate (ADC) candidate generated from its proprietary technology.
› Verified 1 days ago